Did FDA know Ranbaxy meds might be off?

Last week, amid all the brouhaha over the did-Ranbaxy-sell-substandard-meds probe, we reported that Congress had launched an investigation of its own--into just how the FDA handled those allegations once it found out about them. Well, according to a new letter sent to the agency commissioner by the seemingly insatiable investigatory duo of Rep. John Dingell and Rep. Bart Stupak, the agency knew about the accusations for 18 months. And, they say, FDA didn't take steps to pull the products off the market or even tell pharmacists about the suspected problems.

"If true, these statements would call into serious questions whether the leadership of the Agency... [has] met even the minimum requirements" of its mission to police the drug market. The Congressmen want Andrew von Eschenbach to respond to the letter within two weeks.

- see the story in the Wall Street Journal
- get more from ABC News

Suggested Articles

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.